Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel ...

Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported ...

Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in ...

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

In this video, Susana M. Campos, MD, MPH, discusses results from the final analysis of the phase 3 A18 study in advanced cervical cancer, presented at ASCO Annual Meeting.The ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

The vaccine is being developed in partnership with Cleveland Clinic and the phase one trial is fully funded by a grant from ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

This article explores how cancer biomarkers improve early detection, guide treatments and predict outcomes to transform ...